202 related articles for article (PubMed ID: 20373828)
1. An adaptive design for phase II non-oncology dose selection clinical trials.
Su Z
Clin Drug Investig; 2010; 30(6):397-403. PubMed ID: 20373828
[TBL] [Abstract][Full Text] [Related]
2. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
Chang M; Wang J
J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
[TBL] [Abstract][Full Text] [Related]
3. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
6. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
7. Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.
Boonstra PS; Braun TM; Taylor JMG; Kidwell KM; Bellile EL; Daignault S; Zhao L; Griffith KA; Lawrence TS; Kalemkerian GP; Schipper MJ
Ann Oncol; 2017 Jul; 28(7):1427-1435. PubMed ID: 28200082
[TBL] [Abstract][Full Text] [Related]
8. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
9. An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study.
Ivanova A; Liu K; Snyder E; Snavely D
Stat Med; 2009 Oct; 28(24):2941-51. PubMed ID: 19731265
[TBL] [Abstract][Full Text] [Related]
10. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
Sato A; Shimura M; Gosho M
J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
[TBL] [Abstract][Full Text] [Related]
11. Adaptive designs for single-arm phase II trials in oncology.
Englert S; Kieser M
Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
[TBL] [Abstract][Full Text] [Related]
12. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
13. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
Meinzer C; Martin R; Suarez JI
Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
[TBL] [Abstract][Full Text] [Related]
14. Optimal two-stage randomized phase II clinical trials.
Logan BR
Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
[TBL] [Abstract][Full Text] [Related]
15. Adaptive dose finding based on t-statistic for dose-response trials.
Ivanova A; Bolognese JA; Perevozskaya I
Stat Med; 2008 May; 27(10):1581-92. PubMed ID: 18241082
[TBL] [Abstract][Full Text] [Related]
16. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
17. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
18. Using the partitioning principle to adaptively design dose-response studies.
Ling X; Hsu J
J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
[TBL] [Abstract][Full Text] [Related]
19. Adaptive seamless designs with interim treatment selection: a case study in oncology.
Carreras M; Gutjahr G; Brannath W
Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
[TBL] [Abstract][Full Text] [Related]
20. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
Shan G; Ma C; Hutson AD; Wilding GE
J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
